You are viewing the site in preview mode
Skip to main content
| |
160 mg ABT + LPV/r
|
320 mg ABT + LPV/r
|
|---|
|
Randomized and treated
|
10
|
10
|
|
Excluded
|
1
|
1
|
|
SS for safety analysis
|
10
|
10
|
|
ITT for efficacy analysis
|
9
|
9
|
|
Sex (male/female)
|
8/2
|
7/3
|
|
Race (Han/other)
|
9/1
|
10/0
|
|
Age (years)
|
31.9 (18~48)
|
37.4 (24~47)
|
|
Body weight (kg)
|
67.8 (53~88)
|
65.4 (53~76)
|
|
BMI (kg/m2)
|
22.8 (19~27)
|
22.8 (18~26)
|
|
Baseline HIV-1 RNA (log10 copies/ml)
|
4.27 (3.53~4.70)
|
4.27 (3.32~5.14)
|
|
Baseline CD4 (cell/μl)
|
517.0 (350~774)
|
566.6 (350~1070)
|
- Data are presented as n or mean (range)
